Skip to main content
. Author manuscript; available in PMC: 2019 Sep 5.
Published in final edited form as: Leukemia. 2019 Mar 12;33(9):2208–2226. doi: 10.1038/s41375-019-0414-z

Figure 3. HLA-A2 restricted and BCMA antigen-specific immune responses by heteroclitic BCMA72–80 specific CTL against cancer cell lines.

Figure 3

Figure 3

Figure 3

Heteroclitic BCMA72–80 CTL were evaluated for their specific anti-tumor activities. Fig. 3A. Representative flow analyses and summary (mean ± SE; N=3) of CD8+ T cells proliferation (day 5) of h against matched U266 (HLA-A2+ BCMA+) or mis-matcherd MM1S (HLA-A2− BCMA+) and MDA-MB231 (HLA-A2+ BCMA−) cancer cell line. Fig. 3B. Representative flow analyses of CD107a degranulation and Granzyme B/Perforin upregulation by hBCMA72–80 CTL. Fig. 3C. Summary (mean±SE; N=5) of CD107a degranulation, Th1 cytokine (IFN-γ/IL-2/TNF-α) production, and 41BB upregulation in hBCMA72–80 CTL against matched U266 (HLA-A2+ BCMA+) or mis-matched RPMI (HLA-A2− BCMA+) myeloma cell line.